Literature DB >> 15102493

From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

Stephen A Douglas1, Dashyant Dhanak, Douglas G Johns.   

Abstract

The identification of a human homolog of urotensin-II (U-II) and a novel, specific G-protein-coupled receptor by Ames et al. in 1999 changed the perception that the U-II isopeptide family was an esoteric collection of 'somatostatin-like neuropeptides' present only in the nervous systems of an eclectic array of aquatic invertebrates, fish and amphibians. In this article, we review recent developments in the pharmacology of human U-II, focusing on the actions of this peptide in the mammalian cardiorenal system. The putative role of U-II in the etiology of hypertension, heart failure, renal dysfunction and diabetes is discussed, as are novel U-II receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102493     DOI: 10.1016/j.tips.2003.12.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  35 in total

1.  Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.

Authors:  Christophe D Proulx; May Simaan; Emanuel Escher; Stéphane A Laporte; Gaétan Guillemette; Richard Leduc
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

2.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

3.  Dynamic expression pattern of corticotropin-releasing hormone, urotensin I and II genes under acute salinity and temperature challenge during early development of zebrafish.

Authors:  Lei Luo; Aqin Chen; Chongchong Hu; Weiqun Lu
Journal:  Fish Physiol Biochem       Date:  2014-08-26       Impact factor: 2.794

4.  Does cigarette smoking increase plasma urotensin II concentrations?

Authors:  S J Gold; J P Thompson; J P Williams; E E F Helm; J Sadler; W Song; L L Ng; D G Lambert
Journal:  Eur J Clin Pharmacol       Date:  2007-01-25       Impact factor: 2.953

5.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

6.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 7.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

8.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Authors:  D J Behm; J J McAtee; J W Dodson; M J Neeb; H E Fries; C A Evans; R R Hernandez; K D Hoffman; S M Harrison; J M Lai; C Wu; N V Aiyar; E H Ohlstein; S A Douglas
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

9.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

10.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.